NCT05907447

Brief Summary

The aim of this study is to retrospectively collect clinical information on patients with extranodal or rare lymphomas, and to explore the best treatment strategy for these lymphomas in the real-world population.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2023

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 1, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 18, 2023

Completed
13 days until next milestone

Study Start

First participant enrolled

July 1, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

June 18, 2023

Status Verified

June 1, 2023

Enrollment Period

8 months

First QC Date

May 1, 2023

Last Update Submit

June 15, 2023

Conditions

LymphomaExtranodal LymphomaDiffuse Large B Cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaMarginal Zone LymphomaMucosa-Associated Lymphoid Tissue LymphomaNK/T-Cell Lymphoma, Nasal and Nasal-TypeIntravascular Large B-Cell Lymphoma

Keywords

LYMPHOMAEXTRANODAL

Outcome Measures

Primary Outcomes (2)

  • Overall Survival (OS)

    Overall Survival (OS) will be defined from the start date of therapy to the date of death from any cause.

    Baseline up to data cut-off (up to approximately 1 year)

  • Progression Free Survival (PFS)

    Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.

    Baseline up to data cut-off (up to approximately 1 year)

Secondary Outcomes (2)

  • Clinical characteristics form

    Baseline up to data cut-off (up to approximately 1 year)

  • Biological characteristics form

    Baseline up to data cut-off (up to approximately 1 year)

Interventions

No interventions need to be specified for this studyOTHER

No interventions need to be specified for this study

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma with extranodal involvement or non-Hodgkin lymphoma of rare pathological types attending participating centres.

You may qualify if:

  • Age ≥ 18 years (including 18 years old).
  • Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined; Or patients newly diagnosed with non-Hodgkin lymphoma of rare pathological types, including IVLBCL, SMZL, ALCL, AITL, MALTL.
  • Patients who have received systematic clinical treatment.
  • Patients with measurable lesions, at least containing one effective evaluation of efficacy.

You may not qualify if:

  • Patients who only receive supportive treatment.
  • Patients who cannot obtain effective evaluation data of efficacy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, China

Location

MeSH Terms

Conditions

LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Large-Cell, AnaplasticImmunoblastic LymphadenopathyLymphoma, B-Cell, Marginal ZoneLymphoma, Extranodal NK-T-Cell

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLymphoma, B-CellLymphoma, Non-HodgkinLymphoma, T-CellLymphadenopathy

Central Study Contacts

Weili Prof. Zhao

CONTACT

+862164370045zwl_trial@163.com

Pengpeng Prof. Xu

CONTACT

+862164370045pengpeng_xu@126.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

May 1, 2023

First Posted

June 18, 2023

Study Start

July 1, 2023

Primary Completion

March 1, 2024

Study Completion

October 1, 2024

Last Updated

June 18, 2023

Record last verified: 2023-06

Locations

CN(1)